Results 41 to 50 of about 288,395 (355)

Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomised controlled trial [PDF]

, 2014
Background: Only one-third of patients with depression respond fully to treatment with antidepressant medication. However, there is little robust evidence to guide the management of those whose symptoms are 'treatment resistant'.<p></p> ...
Abel, Anna, Barnes, Maria, Button, Katherine, Campbell, John, Carroll, Fran, Garland, Anne, Hollinghurst, Sandra, Jerrom, Bill, Kessler, David, Kuyken, Willem, Lewis, Glyn, Metcalfe, Chris, Morrison, Jill, Odondi, Lang'o, Owen-Smith, Amanda, Peters, Tim, Ridgway, Nicola, Sherlock, Sofie, Thomas, Laura, Turner, Katrina, Turner, Nicholas, Wiles, Nicola, Williams, Chris   +22 more
core   +4 more sources

Antidepressant Drugs [PDF]

Journal of Pain and Symptom Management, 2012
Therapeutic Reviews aim to provide essential independent information for health professionals about drugs used in palliative and hospice care. Additional content is available on www.palliativedrugs.com. Country-specific books (Hospice and Palliative Care Formulary USA, and Palliative Care Formulary, British and Canadian editions) are also available and
Paul, Howard, Robert, Twycross, John, Shuster, Mary, Mihalyo, Andrew, Wilcock   +4 more
openaire   +2 more sources

Methodological Flaws, Conflicts of Interest, and Scientific Fallacies: Implications for the Evaluation of Antidepressants’ Efficacy and Harm

Frontiers in Psychiatry, 2017
BackgroundIn current psychiatric practice, antidepressants are widely and with ever-increasing frequency prescribed to patients. However, several scientific biases obfuscate estimates of antidepressants’ efficacy and harm, and these are barely recognized
Michael P. Hengartner
doaj   +1 more source

Antidepressants for Major Depressive Disorder and Dysthymic Disorder in patients with co-morbid Alcohol Use Disorders: state of the art and a meta-analysis of placebo-controlled randomized trials. [PDF]

, 2011
Major depressive disorder (MDD) and dysthymic disorder (DD) are often complicated by the co-occurrence of alcohol use disorders (AUDs), each condition often aggravating the course and outcome of the other in terms of severity, functional impairment, risk
IOVIENO, NADIA
core  

Five‐Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To provide a comprehensive description of disease progression in synuclein seeding assay (SAA) positive sporadic Parkinson Disease participants, using Neuronal Synuclein Disease integrated biological and functional impairment staging framework.
Paulina Gonzalez‐Latapi, Caroline Gochanour, Seung Ho Choi, Hyunkeun Cho, Chelsea Caspell‐Garcia, Christopher Coffey, Michael Brumm, David‐Erick Lafontant, Yuge Xiao, Thomas Tropea, John Seibyl, Caroline Tanner, Charles S. Venuto, Karl Kieburtz, Lana M. Chahine, Kathleen L. Poston, Andrew Siderowf, Kenneth Marek, Tanya Simuni, The Parkinson's Progression Markers Initiative   +19 more
wiley   +1 more source

Is the Comparison between Exercise and Pharmacologic Treatment of Depression in the Clinical Practice Guideline of the American College of Physicians Evidence-Based?

Frontiers in Pharmacology, 2017
Major depression disorder is most commonly treated with antidepressants. However, due to their side effects clinicians seek non-pharmacologic options, and one of these is exercise.
Yael Netz
doaj   +1 more source

Prevalence of patients treated with antidepressant medicine in Greenland and Denmark: a cross-sectional study

International Journal of Circumpolar Health, 2021
Depression is a mental illness affecting more than 260 million people worldwide. In Greenland, the prevalence of patients treated with antidepressant medicine (antidepressants) has not previously been investigated.
Tukummeq Nykjær Ingemann, Marie Balslev Backe, Eva C. Bonefeld-Jørgensen, Nils Skovgaard, Michael Lynge Pedersen   +4 more
doaj   +1 more source

Antidepressants and age [PDF]

, 2011
Antidepressants as a commodity have been remarkably little-studied by economists. This study shows in new data for 27 European countries that 8% of people (and 10% of those middle-aged) take antidepressants each year.
Blanchflower, David G., Oswald, Andrew J.   +1 more
core   +1 more source

Effects of Imipramine and Lithium on the Suppression of Cell Proliferation in the Dentate Gyrus of the Hippocampus in Adrenocorticotropic Hormone-treated Rats [PDF]

, 2010
We examined the influence of chronic adrenocorticotropic hormone (ACTH) treatment on the number of Ki-67-positive cells in the dentate gyrus of the hippocampus in rats. ACTH treatment for 14 days decreased the number of such cells.
Asanuma, Masato, Doi, Maho, Gomita, Yutaka, Kawasaki, Hiromu, Kitamura, Yoshihisa, Matsunaga, Hisashi, Miyazaki, Ikuko, Nagamachi, Tomoko, Sendo, Toshiaki, Shinomiya, Kazuaki   +9 more
core   +1 more source

Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker‐Defined Synucleinopathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal state for Lewy body disorders and exhibits biological heterogeneity that may influence clinical expression and progression. We examined clinical features in individuals with iRBD and biomarker‐defined synucleinopathy.
Daniel Weintraub, Michele K. York, Roseanne Dobkin, Anuprita R. Nair, Ryan Kurth, David‐Erick Lafontant, Chelsea Caspell‐Garcia, Roy N. Alcalay, Ethan G. Brown, Lana M. Chahine, Christopher Coffey, Tatiana Foroud, Douglas Galasko, Karl Kieburtz, Kenneth Marek, Kalpana Merchant, Brit Mollenhauer, Kathleen L. Poston, Andrew Siderowf, Cristina Simonet, Tanya Simuni, Caroline M. Tanner, Thomas F. Tropea, Aleksandar Videnovic, The Parkinson's Progression Markers Initiative   +24 more
wiley   +1 more source